Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.56 |
| ▸ | MC4R | P32245 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22014479 | 0.86 | SIGMAR1 (0.58) | SIGMAR1MC4RLMNAPOLBALDH1A1 | |
| SCHEMBL22014091 | 0.83 | SIGMAR1 (0.64) | SIGMAR1MC4RLMNAPOLBALDH1A1 | |
| SCHEMBL22014474 | 0.81 | SIGMAR1 (0.51) | SIGMAR1MC4RLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL22014478 | 0.80 | POLB (0.58) | SIGMAR1MC4RLMNAPOLBALDH1A1 | |
| SCHEMBL22014093 | 0.79 | SIGMAR1 (0.58) | SIGMAR1MC4RLMNAPOLBALDH1A1 | |
| SCHEMBL14204465 | 0.79 | MAPT (0.56) | POLBALDH1A1MAPK1KMT2AKDM4E | |
| SCHEMBL22355488 | 0.79 | SIGMAR1 (0.49) | SIGMAR1MC4RLMNAALDH1A1SMN1; SMN2 | |
| Methyl Alcohol SCHEMBL27657573 | 0.77 | SIGMAR1 (0.86) | SIGMAR1MC4RLMNAPOLBALDH1A1 | |
| SCHEMBL7421122 | 0.77 | SIGMAR1 (0.55) | SIGMAR1MC4RLMNAPOLBALDH1A1 | |
| SCHEMBL8188324 | 0.75 | SIGMAR1 (1.00) | SIGMAR1MC4RLMNAPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11344635-B2 | Compounds for use as iron (III) MRI contrast agents containing anionic pendents and ancillary groups | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2020102820-A1 | COMPOUNDS FOR USE AS IRON (III) MRI CONTRAST AGENTS CONTAINING ANIONIC PENDENTS AND ANCILLARY GROUPS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344635-B2 | Compounds for use as iron (III) MRI contrast agents containing anionic pendents and ancillary groups | SLC40A1, TAC3, ABCB7 | SIGMAR1 1907/4885MC4R 1330/4885LMNA 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.